Bioinvent

BioInvent is a biopharmaceutical company that specializes in the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer treatment. The company's primary focus is the design of new therapeutic antibodies that can harness the body's own immune system to fight cancer.

History

BioInvent was founded in Lund, Sweden in 1997. The company has since grown to become a leading player in the field of oncology, with a strong focus on the development of innovative immunotherapy treatments.

Research and Development

BioInvent's research and development activities are primarily focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer treatment. The company's proprietary n-CoDeR library and F.I.R.S.T platform are used to identify and develop these antibodies.

The n-CoDeR library is a vast collection of fully human antibodies, while the F.I.R.S.T platform is a unique screening tool that allows for the simultaneous identification of antibodies that bind to tumor cells and immune effector cells.

Products

BioInvent's lead product candidate is BI-1206, a monoclonal antibody that is currently in clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia. The company is also developing several other antibodies for the treatment of various types of cancer.

Partnerships

BioInvent has established several strategic partnerships with leading pharmaceutical and biotechnology companies. These partnerships have enabled the company to accelerate the development of its product candidates and expand its pipeline.

See Also

• Biopharmaceutical
• Immunotherapy
• Oncology
• Antibody